Lymphoma Clinical Trials
1) 2ND line or greater/ SGN35-031: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2) CTMX-M-2029-001 (CytomX) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas.
3) MOR208C310 frontMIND: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
4)NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
FOLLICULAR LYMPHOMA Grade 1 to 3a or R/R Marginal Zone Lymphoma (2)
1) INCMOR 0208-301 inMIND: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.
2) NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.
Send UsA Message
Early-Stage Breast Cancer Characteristics and Treatment Options
Early-Stage Breast Cancer Characteristics and Treatment OptionsA rise in early-stage breast cancer diagnosis may result from better screening technology and a raised awareness of the importance of annual mammograms. An early-stage breast cancer diagnosis is contained...
Game Changing Neoadjuvant Lung Trial Enrolls the Most People in the World
Charleston Oncology’s Clinical Trials most recent non–small cell lung cancer trial enrolled the most people in the world. Gene Saylors, MD, oncologist and hematologist at Charleston Oncology, will present the positive findings at the American Association for Cancer Research 2022 Annual Meeting. “When administering a new trial, we are always cautiously optimistic,” says Dr. Gene Saylors. “The positive results of this Neoadjuvant Lung Trial resulted in rapid FDA approval due to its impressive outcomes.”
Lowcountry doctors, patients helped secure ‘game-changer’ cancer treatment approval
Clinical trials for a newly-approved cancer treatment for lung cancer in the Lowcountry helped get the drug ready for people around the world, Lowcountry medical officials say.
Lowcountry Breast Cancer Survivors On Finding The Right Oncology Practice
How should one go about finding the right oncology practice? We interviewed ten Lowcountry breast cancer patients to get their perspectives and advice.
Sarcoma and Bone Cancer Awareness
July is Sarcoma and Bone Cancer Awareness Month. Sarcomas are a rare group of cancers in which malignant cells form in the bones or soft tissues of the body.
May is Skin Cancer Awareness Month
Melanoma is a type of skin cancer that develops when melanocytes start to grow out of control. Watch a video to learn more about melanoma from Dr. Charles S. Holladay.
